Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.

@article{Tohn2011StimulationOA,
  title={Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.},
  author={Robert Tohn and Hartley Blumenfeld and S M Mansour Haeryfar and Natacha Veerapen and Gurdal S. Besra and Steven A. Porcelli and Terry L. Delovitch},
  journal={Clinical and experimental immunology},
  year={2011},
  volume={164 1},
  pages={26-41}
}
We have reported previously that treatment of non-obese diabetic (NOD) mice with the invariant natural killer T (iNK T) cell agonist α-galactosylceramide C26:0 (α-GalCer) or its T helper type 2 (Th2)-biasing derivative α-GalCer C20:2 (C20:2) protects against type 1 diabetes (T1D), with C20:2 yielding greater protection. After an initial response to α-GalCer, iNK T cells become anergic upon restimulation. While such anergic iNK T cells can induce tolerogenic dendritic cells (DCs) that mediate… CONTINUE READING
Highly Cited
This paper has 26 citations. REVIEW CITATIONS

7 Figures & Tables

Connections & Topics

Mentioned Connections BETA
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
We have reported previously that treatment of non - obese diabetic ( NOD ) mice with the invariant natural killer T ( iNK T ) cell agonist α-galactosylceramide C26:0 ( α-GalCer ) or its T helper type 2 ( Th2)-biasing derivative α-GalCer C20:2 ( C20:2 ) protects against type 1 diabetes ( T1D ) , with C20:2 yielding greater protection .
All Topics